

Audit Review Table

Molina Healthcare of New Mexico (Org ID: 955, SubID: 4112, Medicaid, Spec Area: None, Spec Proj: None); Measurement Year - 2014

The Auditor lock has been applied to this submission.

Measure/Data Element	Report Measure	Benefit Offered	Rotated Measure	Rate	Reportable	Comment
Effectiveness of Care: Prevention and Screening						
Adult BMI Assessment (aba)	Y		N	74.48%	R	Reportable
Weight Assessment and Counseling for Nutrition and Physical Activity for Children/Adolescents (wcc)	Y		N			
<i>BMI Percentile</i>				34.96%	R	Reportable
<i>Counseling for Nutrition</i>				53.32%	R	Reportable
<i>Counseling for Physical Activity</i>				49.34%	R	Reportable
Childhood Immunization Status (cis)	Y		N			
<i>DTaP</i>				83.00%	R	Reportable
<i>IPV</i>				93.16%	R	Reportable
<i>MMR</i>				93.38%	R	Reportable
<i>HiB</i>				93.16%	R	Reportable
<i>Hepatitis B</i>				92.94%	R	Reportable
<i>VZV</i>				92.94%	R	Reportable
<i>Pneumococcal Conjugate</i>				82.56%	R	Reportable
<i>Hepatitis A</i>				89.62%	R	Reportable
<i>Rotavirus</i>				76.38%	R	Reportable
<i>Influenza</i>				54.53%	R	Reportable
<i>Combination #2</i>				80.79%	R	Reportable
<i>Combination #3</i>				77.70%	R	Reportable
<i>Combination #4</i>				75.06%	R	Reportable
<i>Combination #5</i>				66.45%	R	Reportable
<i>Combination #6</i>				50.33%	R	Reportable
<i>Combination #7</i>				64.24%	R	Reportable
<i>Combination #8</i>				49.45%	R	Reportable
<i>Combination #9</i>				45.70%	R	Reportable
<i>Combination #10</i>				44.81%	R	Reportable
Immunizations for Adolescents (ima)	Y		N			
<i>Meningococcal</i>				63.91%	R	Reportable

<i>Tdap/Td</i>				75.86%	R	Reportable
<i>Combination #1</i>				61.15%	R	Reportable
Human Papillomavirus Vaccine for Female Adolescents (hvp)	Y			27.87%	R	Reportable
Lead Screening in Children (lsc)	Y		N	40.40%	R	Reportable
Breast Cancer Screening (bcs)	Y			71.41%	R	Reportable
Cervical Cancer Screening (ccs)	Y			45.81%	R	Reportable
Non-Recommended Cervical Cancer Screening in Adolescent Females (ncs)	Y			3.60%	R	Reportable
Chlamydia Screening in Women (chl)	Y					
<i>16-20 Years</i>				42.16%	R	Reportable
<i>21-24 Years</i>				55.93%	R	Reportable
<i>Total</i>				48.24%	R	Reportable
Effectiveness of Care: Respiratory Conditions						
Appropriate Testing for Children with Pharyngitis (cwp)	Y	Y		67.59%	R	Reportable
Appropriate Treatment for Children With URI (uri)	Y	Y		85.80%	R	Reportable
Avoidance of Antibiotic Treatment in Adults with Acute Bronchitis (aab)	Y	Y		27.01%	R	Reportable
Use of Spirometry Testing in the Assessment and Diagnosis of COPD (spr)	Y			24.53%	R	Reportable
Pharmacotherapy Management of COPD Exacerbation (pce)	Y	Y				
<i>Systemic Corticosteroid</i>				46.60%	R	Reportable
<i>Bronchodilator</i>				61.42%	R	Reportable
Use of Appropriate Medications for People With Asthma (asm)	Y	Y				
<i>5-11 Years</i>				89.84%	R	Reportable
<i>12-18 Years</i>				84.40%	R	Reportable
<i>19-50 Years</i>				77.63%	R	Reportable
<i>51-64 Years</i>				70.21%	R	Reportable

<i>Total</i>				83.08%	R	Reportable
Medication Management for People With Asthma (mma)	Y	Y				
<i>5-11 Years - Medication Compliance 50%</i>				46.23%	R	Reportable
<i>5-11 Years - Medication Compliance 75%</i>				23.12%	R	Reportable
<i>12-18 Years - Medication Compliance 50%</i>				44.22%	R	Reportable
<i>12-18 Years - Medication Compliance 75%</i>				19.14%	R	Reportable
<i>19-50 Years - Medication Compliance 50%</i>				47.88%	R	Reportable
<i>19-50 Years - Medication Compliance 75%</i>				25.85%	R	Reportable
<i>51-64 Years - Medication Compliance 50%</i>				56.57%	R	Reportable
<i>51-64 Years - Medication Compliance 75%</i>				30.30%	R	Reportable
<i>Total - Medication Compliance 50%</i>				47.01%	R	Reportable
<i>Total - Medication Compliance 75%</i>				23.26%	R	Reportable
Asthma Medication Ratio (amr)	Y	Y				
<i>5-11 Years</i>				60.95%	R	Reportable
<i>12-18 Years</i>				51.69%	R	Reportable
<i>19-50 Years</i>				44.41%	R	Reportable
<i>51-64 Years</i>				49.65%	R	Reportable
<i>Total</i>				52.98%	R	Reportable
Effectiveness of Care: Cardiovascular Conditions						
Controlling High Blood Pressure (cbp)	Y			49.88%	R	Reportable
Persistence of Beta-Blocker Treatment After a Heart Attack (pbh)	Y	Y		57.69%	R	Reportable
Effectiveness of Care: Diabetes						
Comprehensive Diabetes Care (cdc)	Y		N			
<i>Hemoglobin A1c (HbA1c) Testing</i>				85.65%	R	Reportable
<i>HbA1c Poor Control (>9.0%)</i>				49.89%	R	Reportable
<i>HbA1c Control (<8.0%)</i>				37.75%	R	Reportable
<i>HbA1c Control (<7.0%)</i>				NR	NR	Plan chose not to report
<i>Eye Exam (Retinal) Performed</i>				56.51%	R	Reportable
<i>Medical Attention for Nephropathy</i>				74.83%	R	Reportable
<i>Blood Pressure Control (<140/90 mm Hg)</i>				59.38%	R	Reportable
Effectiveness of Care: Musculoskeletal Conditions						

Disease Modifying Anti-Rheumatic Drug Therapy in Rheumatoid Arthritis (art)	Y	Y		68.39%	R	Reportable
Use of Imaging Studies for Low Back Pain (lbp)	Y			73.16%	R	Reportable
Effectiveness of Care: Behavioral Health						
Antidepressant Medication Management (amm)	Y	Y				
<i>Effective Acute Phase Treatment</i>				53.50%	R	Reportable
<i>Effective Continuation Phase Treatment</i>				38.63%	R	Reportable
Follow-Up Care for Children Prescribed ADHD Medication (add)	Y	Y				
<i>Initiation Phase</i>				55.13%	R	Reportable
<i>Continuation and Maintenance (C&M) Phase</i>				68.16%	R	Reportable
Follow-Up After Hospitalization for Mental Illness (fuh)	Y	Y				
<i>30-Day Follow-Up</i>				64.80%	R	Reportable
<i>7-Day Follow-Up</i>				41.80%	R	Reportable
Diabetes Screening for People With Schizophrenia or Bipolar Disorder Who Are Using Antipsychotic Medication (ssd)	Y	Y		76.98%	R	Reportable
Diabetes Monitoring for People With Diabetes and Schizophrenia (smd)	Y			57.86%	R	Reportable
Cardiovascular Monitoring for People With Cardiovascular Disease and Schizophrenia (smc)	Y			NA	R	Denominator fewer than 30
Adherence to Antipsychotic Medications for Individuals With Schizophrenia (saa)	Y	Y		58.67%	R	Reportable
Use of Multiple Concurrent Antipsychotics in Children and Adolescents (apc)	Y	Y				
<i>1-5 Years</i>				NA	R	Denominator fewer than 30
<i>6-11 Years</i>				5.88%	R	Reportable
<i>12-17 Years</i>				3.98%	R	Reportable

<i>Total</i>				4.60%	R	Reportable
Metabolic Monitoring for Children and Adolescents on Antipsychotics (apm)	Y	Y				
<i>1-5 Years</i>				NA	R	Denominator fewer than 30
<i>6-11 Years</i>				24.84%	R	Reportable
<i>12-17 Years</i>				32.11%	R	Reportable
<i>Total</i>				29.01%	R	Reportable
Effectiveness of Care: Medication Management						
Annual Monitoring for Patients on Persistent Medications (mpm)	Y	Y				
<i>ACE Inhibitors or ARBs</i>				83.11%	R	Reportable
<i>Digoxin</i>				60.00%	R	Reportable
<i>Diuretics</i>				83.22%	R	Reportable
<i>Total</i>				83.07%	R	Reportable
Access/Availability of Care						
Adults' Access to Preventive/Ambulatory Health Services (aap)	Y					
<i>20-44 Years</i>				76.31%	R	Reportable
<i>45-64 Years</i>				84.75%	R	Reportable
<i>65+ Years</i>				86.82%	R	Reportable
<i>Total</i>				79.48%	R	Reportable
Children and Adolescents' Access to Primary Care Practitioners (cap)	Y					
<i>12-24 Months</i>				95.51%	R	Reportable
<i>25 Months - 6 Years</i>				88.11%	R	Reportable
<i>7-11 Years</i>				92.00%	R	Reportable
<i>12-19 Years</i>				91.43%	R	Reportable
Annual Dental Visit (adv)	Y	Y				
<i>2-3 Years</i>				51.07%	R	Reportable
<i>4-6 Years</i>				67.85%	R	Reportable
<i>7-10 Years</i>				71.02%	R	Reportable
<i>11-14 Years</i>				66.16%	R	Reportable
<i>15-18 Years</i>				57.06%	R	Reportable

19-21 Years				35.45%	R	Reportable
Total				62.75%	R	Reportable
Initiation and Engagement of AOD Dependence Treatment (iet)	Y	Y				
Initiation of AOD Treatment: 13-17 Years				46.57%	R	Reportable
Engagement of AOD Treatment: 13-17 Years				17.60%	R	Reportable
Initiation of AOD Treatment: 18+ Years				38.89%	R	Reportable
Engagement of AOD Treatment: 18+ Years				13.08%	R	Reportable
Initiation of AOD Treatment: Total				39.52%	R	Reportable
Engagement of AOD Treatment: Total				13.45%	R	Reportable
Prenatal and Postpartum Care (ppc)	Y					
Timeliness of Prenatal Care				76.80%	R	Reportable
Postpartum Care				54.50%	R	Reportable
Call Answer Timeliness (cat)	Y			93.68%	R	Reportable
Use of First-Line Psychosocial Care for Children and Adolescents on Antipsychotics (app)	Y	Y				
1-5 Years				NA	R	Denominator fewer than 30
6-11 Years				58.67%	R	Reportable
12-17 Years				52.41%	R	Reportable
Total				53.78%	R	Reportable
Utilization						
Frequency of Ongoing Prenatal Care (fpc)	Y					
<21 Percent				9.01%	R	Reportable
21-40 Percent				7.66%	R	Reportable
41-60 Percent				8.33%	R	Reportable
61-80 Percent				13.96%	R	Reportable
81+ Percent				61.04%	R	Reportable
Well-Child Visits in the First 15 Months of Life (w15)	Y		N			
0 Visits				3.28%	R	Reportable
1 Visit				1.87%	R	Reportable
2 Visits				3.51%	R	Reportable
3 Visits				7.03%	R	Reportable
4 Visits				11.24%	R	Reportable
5 Visits				21.31%	R	Reportable

6+ Visits				51.76%	R	Reportable
Well-Child Visits in the Third, Fourth, Fifth and Sixth Years of Life (w34)	Y		N	63.57%	R	Reportable
Adolescent Well-Care Visits (awc)	Y		N	51.66%	R	Reportable
Frequency of Selected Procedures (fsp)	Y				R	Reportable
Ambulatory Care: Total (amba)	Y				R	Reportable
Ambulatory Care: Dual Eligibles (ambb)	N				NR	Measure Unselected
Ambulatory Care: Disabled (ambc)	N				NR	Measure Unselected
Ambulatory Care: Other (ambd)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Total (ipua)	Y				R	Reportable
Inpatient Utilization--General Hospital/Acute Care: Dual Eligibles (ipub)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Disabled (ipuc)	N				NR	Measure Unselected
Inpatient Utilization--General Hospital/Acute Care: Other (ipud)	N				NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Total (iada)	Y	Y			R	Reportable
Identification of Alcohol and Other Drug Services: Dual Eligibles (iadb)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Disabled (iadc)	N	N			NR	Measure Unselected
Identification of Alcohol and Other Drug Services: Other (iadd)	N	N			NR	Measure Unselected
Mental Health Utilization: Total (mpta)	Y	Y			R	Reportable
Mental Health Utilization: Dual Eligibles (mptb)	N	N			NR	Measure Unselected
Mental Health Utilization: Disabled (mptc)	N	N			NR	Measure Unselected
Mental Health Utilization: Other (mptd)	N	N			NR	Measure Unselected
Antibiotic Utilization: Total (abxa)	Y	Y			R	Reportable
Antibiotic Utilization: Dual Eligibles (abxb)	N	N			NR	Measure Unselected
Antibiotic Utilization: Disabled (abxc)	N	N			NR	Measure Unselected
Antibiotic Utilization: Other (abxd)	N	N			NR	Measure Unselected

Relative Resource Use						
Relative Resource Use for People With Diabetes (rdi)	Y				R	Reportable
Relative Resource Use for People With Asthma (ras)	Y	Y			R	Reportable
Relative Resource Use for People With Cardiovascular Conditions (rca)	Y				R	Reportable
Relative Resource Use for People With Hypertension (rhy)	Y				R	Reportable
Relative Resource Use for People With COPD (rco)	Y				R	Reportable
Health Plan Descriptive Information						
Board Certification (bcr)	N				NR	Measure Unselected
Total Membership (tlm)	Y				R	Reportable
Enrollment by Product Line: Total (enpa)	Y				R	Reportable
Enrollment by Product Line: Dual Eligibles (enpb)	N				NR	Measure Unselected
Enrollment by Product Line: Disabled (enpc)	N				NR	Measure Unselected
Enrollment by Product Line: Other (enpd)	N				NR	Measure Unselected
Enrollment by State (ebs)	Y				R	Reportable
Race/Ethnicity Diversity of Membership (rdm)	Y				R	Reportable
Language Diversity of Membership (ldm)	Y				R	Reportable
Weeks of Pregnancy at Time of Enrollment (wop)	Y				R	Reportable